Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0112077" target="_blank" >RIV/00843989:_____/25:E0112077 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/25:10159687 RIV/00216208:11110/25:10507923 RIV/61989592:15110/25:73633213 RIV/00023761:_____/25:N0000012 RIV/00064165:_____/25:10507923

Výsledek na webu

<a href="https://doi.org/10.1080/0886022X.2025.2609353" target="_blank" >https://doi.org/10.1080/0886022X.2025.2609353</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/0886022X.2025.2609353" target="_blank" >10.1080/0886022X.2025.2609353</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy

Popis výsledku v původním jazyce

IgA nephropathy (IgAN) is characterized by the deposition of galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes into kidney mesangium leading to glomerular inflammation and injury. In patients with active IgAN non-responding to renin-angiotensin system blocking drugs (RASBs), corticosteroids (CSs) are recommended. Although CSs reduce significantly serum levels of Gd-IgA1, IgA-containing immune complexes, and proteinuria, their clinical effect in IgAN is variable. Because IgAN patients exhibit abnormal serum concentration of several endogenous steroid metabolites, some of which exhibit immuno-protective/regulating functions, we analyzed serum metabolites which could predict clinical response to CS therapy. This prospective study was performed in 18 male IgAN patients to identify potential biomarkers for personalized CS therapy. Using LC-MS set of 85 steroid metabolites was tested in the sera of IgAN patients before CS therapy initiation to identify those with statistically different level in patients clinically responding and not-responding to CS therapy. Responders were those subjects whose proteinuria decrease below 1 g/day after 6-12 months of CS therapy. Statistical analysis revealed significant and clinically relevant differences in the steroid profile between responders and non-responders. The key and consistent finding across the entire analysis is that non-responder status is associated with globally higher level of almost all analyzed steroids. The response of IgAN patients to CS therapy could be predicted by measuring the serum levels of selected steroid metabolites to receive steroid profile. Observation needs to be confirmed in large cohorts of various ethnic origin to be applicable for routine clinical protocols.

Název v anglickém jazyce

Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy

Popis výsledku anglicky

IgA nephropathy (IgAN) is characterized by the deposition of galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes into kidney mesangium leading to glomerular inflammation and injury. In patients with active IgAN non-responding to renin-angiotensin system blocking drugs (RASBs), corticosteroids (CSs) are recommended. Although CSs reduce significantly serum levels of Gd-IgA1, IgA-containing immune complexes, and proteinuria, their clinical effect in IgAN is variable. Because IgAN patients exhibit abnormal serum concentration of several endogenous steroid metabolites, some of which exhibit immuno-protective/regulating functions, we analyzed serum metabolites which could predict clinical response to CS therapy. This prospective study was performed in 18 male IgAN patients to identify potential biomarkers for personalized CS therapy. Using LC-MS set of 85 steroid metabolites was tested in the sera of IgAN patients before CS therapy initiation to identify those with statistically different level in patients clinically responding and not-responding to CS therapy. Responders were those subjects whose proteinuria decrease below 1 g/day after 6-12 months of CS therapy. Statistical analysis revealed significant and clinically relevant differences in the steroid profile between responders and non-responders. The key and consistent finding across the entire analysis is that non-responder status is associated with globally higher level of almost all analyzed steroids. The response of IgAN patients to CS therapy could be predicted by measuring the serum levels of selected steroid metabolites to receive steroid profile. Observation needs to be confirmed in large cohorts of various ethnic origin to be applicable for routine clinical protocols.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Renal failure

ISSN

0886-022X

e-ISSN

1525-6049

Svazek periodika

47

Číslo periodika v rámci svazku

article 2609353

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

1-11

Kód UT WoS článku

001654586200001

EID výsledku v databázi Scopus

2-s2.0-105026638627